Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: A pilot prospective randomised double-blind parallel group trial

International Journal of Cardiology

Volumn 78, Issue 3, 2001, Pages 241-246

  Li Saw Hee, Foo Leong ^a   Beevers, D Gareth ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Enalapril; Fibrinogen; Losartan; Plasminogen activator inhibitor (PAI); Soluble P selectin; Von Willebrand factor (vWf)

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE ACTIVATION; THROMBOGENESIS; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; ENALAPRIL; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; P-SELECTIN; PILOT PROJECTS; PLASMINOGEN INACTIVATORS; PROSPECTIVE STUDIES; RECEPTORS, ANGIOTENSIN; STATISTICS, NONPARAMETRIC; VON WILLEBRAND FACTOR;

EID: 0034980621     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00380-1     Document Type: Article

References (25)

1. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for regression dilution bias
2. Does hypertension confer a hypercoagulable state?
3. The role of rheology and haemostatic factors in hypertension
4. Fibrinogen and cardiovascular disease
5. Von Willebrand factor and endothelial damage in essential hypertension
6. Relationship of endothelium, thrombogenesis, and haemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy
7. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension
8. Effects of long-acting propanolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension
9. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension
10. Decreased blood viscosity and serum levels of erythropoietin after antihypertensive treatment with amlodipine or metoprolol: Results of a cross-over study
11. The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension
12. Comparison of cilazapril and nifedipine retard on ambulatory blood pressure, metabolic, rheological and platelet function in hypertensive patients
13. Effect of captopril and enalapril on endothelial function in hypertensive patients
14. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension
15. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2
16. Microalbuminuria and endothelial dysfunction in essential hypertension
17. Von Willebrand factor antigen and fibronectin in essential hypertension
18. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension
19. Haemostasis balance disorders in patients with essential hypertension
20. Association between blood pressure and fibrinolytic potential in the Framingham Offspring population
21. Haemostasis in normotensive and hypertensive men - Results of the PROCAM study
22. Evidence of platelet activation in hypertension
23. Effects of acute angiotensin II Type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
24. Von Willebrand factor and soluble E-selectin in hypertension: Influence of treatment and value in predicting the progression of atherosclerosis